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vailable  online  19  April  2015 68-year-old  man  with  history  of  hypertension,  type  2  dia-
etes  mellitus,  coronary  artery  disease,  aortic  stenosis  and
hronic  kidney  disease.  Relevant  medications  included  biso-
rolol,  furosemide,  atorvastatin,  perindopril/amlodipine,
etformin/sitagliptin  and  aspirin.  The  patient  was  admit-
ed  in  the  emergency  department  for  acute  decompensated
eart  failure  and  acute-on-chronic  renal  failure  with  hyper-
alemia.  He  began  treatment  with  cation  exchange  resin
40  g/day),  which  was  continued  for  3  days.  On  the  fourth
ay  of  hospitalization,  the  patient  presented  hematochezia
ith  hemodynamic  repercussion  and  anemia  (hemoglobin,
.5  g/dl).  Two  units  of  packed  red  blood  cells  have  been
ransfused  and  an  endoscopic  examination  was  requested,
he  colonoscopy  revealed  three  ulcers  with  about  10  mm,
ongested  and  edematous  surrounding  mucosa,  in  the  prox-
mal  ascending  colon  (Fig.  1).  Histological  evaluation  of  the
lcer  biopsies  identiﬁed  several  rhomboid  crystals  of  sodium
olystyrene  sulfonate.  This  clinical  case  was  assumed  to  be  a
odium  polystyrene  sulfonate-induced  colitis  (Figs.  2 and  3).
he  patient  was  discharged  without  evidence  of  rebleeding.∗ Corresponding author.
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C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4Figure  1  A  colonoscopy  shows  ulceration  in  the  right  colon.
Sodium  polystyrene  sulfonate  (SPS)  is  a  drug  used  in  the
reatment  of  hyperkalemia.  Its  action  begins  in  the  stomach,
ith  the  exchange  of  sodium  ions  for  hydrogen  ions  that,
long  the  digestive  tract,  are  exchanged  for  potassium  ions,
hich  are,  in  turn,  eliminated  in  the  feces,  consequently
 by Elsevier España, S.L.U. This is an open access article under the
.0/).
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Figure  2  Microscopically,  intestinal  mucosa  shows  ischemic
changes  and  the  presence  of  dense  polygonal  basophilic  crystals
within  the  granulation  tissue  and  the  ulcer  bed  (40×  HE).
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4Figure  3  Polystyrene  sulfonate  crystals  with  their  character-
istic  mosaic  pattern  (400×  HE).
reducing  the  levels  of  serum  potassium.  SPS  can  cause  con-
stipation  and  fecal  impaction,  and  is  often  administrated
combined  with  sorbitol  or  other  hypertonic  laxative.  The
mechanism  of  injury  to  the  mucosa  of  the  gastrointesti-
nal  tract  is  not  yet  clear:  It  is  believed  that  the  sorbitol
additive,  due  to  its  cathartic  effect,  induces  changes  in  the
intestinal  microcirculation  vasculature  and  that  its  osmotic
action  results  in/contributes  to  direct  mucosal  injury.1 In
our  case,  sorbitol  or  other  laxative  was  not  concomitantly
administered,  likewise  in  a  previous  case  report  described
by  Tapaya  et  al.2 Such  fact  suggests  that  the  adverse  effect
5127
s  not  correlated  with  the  use  of  laxatives,  but  SPS  may
ave  a signiﬁcant  role  inducing  digestive  tract  lesions.  Colitis
ue  to  SPS  occurs  in  1%  of  the  cases,  especially  in  post-
urgical  patients  and  patients  with  advanced  renal  disease,
he  last  condition  as  was  the  case  of  our  patient.3,4 Clinical
resentation  varies,  ranging  from  abdominal  pain,  nausea,
iarrhea  and  hematochezia.  Endoscopic  ﬁndings  are  non-
peciﬁc:  mucosal  edema,  ulcers,  pseudomembranes  and,
n  more  severe  cases,  necrosis  and  intestinal  perforation.4
escriptions  of  previous  cases  indicate  that  symptoms  can
ppear  up  to  11  days  after  the  drug’s  administration,  in
ur  patient,  the  symptoms  appeared  3  days  after  taking
PS,  suggesting  its  early  adverse  effect.  Several  differential
iagnoses,  such  as  inﬂammatory  bowel  disease,  infection
nd  ischemia  should  be  considered;  therefore,  the  histo-
ogical  analysis  of  the  biopsies  is  essential  for  deﬁnitive
iagnosis.  Microscopically,  the  biopsy  specimens  showed
olygonal  crystals,  basophilic  and  nonpolaring,  with  mosaic
attern.5 Patient  management  includes  supportive  care,
voiding  drugs  and,  in  the  most  severe  cases,  intestinal
esection  may  be  required.
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